RICHMOND, Va.--(BUSINESS WIRE)--June 17, 2003--Insmed Incorporated (Nasdaq:INSM) announced today that the Company has been selected to present to the Biotechnology Industry Organization Annual Convention, BIO 2003, to take place June 22-25 at the Washington Convention Center, Washington, D.C. The presentation will take place on Monday, June 23 at 11:15 a.m. Eastern Time. Geoffrey Allan, Ph.D., president and chief executive officer of Insmed, will provide an update on the rhIGF-I/rhIGFBP-3 clinical development program and the Company's key corporate initiatives.
The presentation will be webcast live, and a recording will be made available following the presentation. The webcast and recording will be available on Insmed's corporate website, www.insmed.com. To access the webcast, please log on to Insmed's website approximately ten minutes prior to the presentation to register and download any necessary audio or visual software.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases with unmet medical needs. For further information about Insmed and rhIGF-I/rhIGFBP-3, please visit the company's corporate website at www.insmed.com.
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.
CONTACT: Insmed, Inc. Baxter Phillips, III, 804/565-3041; bphillips@insmed.com
